For Maria Sampalis, OD, implementing AI isn't an excuse for practice owners to replace their staff with new technology; it should instead lift the burden of certain tasks to make for more patient visits.
|Podcasts|April 9, 2021
Podcast: Visus presbyopia drop gets FDA IND OK
A presbyopia-correcting eyedrop recently received FDA acceptance of its investigational new drug (IND) application
Advertisement
Rhett Schiffman, MD, MHSA, chief medical officer and head of research and development at Visus Therapeutics, talks with Gretchyn Bailey, NCLC, FAAO, editor in chief of Optometry Times® about Brimichol, the company’s presbyopia-correcting eyedrop that recently received FDA acceptance of its investigational new drug (IND) application.
Advertisement
Related to this article
Walline, American Academy of Optometry president, shares this year's conference attendance numbers, clinical pearls, and what he hopes to see in 2027.
Thomas Wong, OD, FAAO, details a session he presented alongside Ronald Gentile, MD, FACS, FASRS, at AAOpt 2026.
Christina M. Danley, OD, FOVDR, explores the many nuances that require consideration when answering a common question asked by parents of children with myopia.
Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.
Raman Bhakhri, OD, FAAO, alongside Xiao Yu, OD, FAAO, discussed emerging investigational therapies for the disease during their AAOpt 2026 session.
A single Epioxa epi-on cross-linking treatment sustained a 1.9 D Kmax improvement through three years in keratoconus, with no serious adverse events reported.
Jamie Kuzniar, OD, FAAO, FSLS, discusses a case-based AAOpt 2026 session on scleral lens complications, fitting around cross-linking, and advice for new graduates.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
The screen time question: What to ask and when to look deeper
2
AAOpt 2026: Current controversies in macular hole diagnosis, management
3
AAOpt 2026: Jeffrey Walline, OD, PhD, on his conference takeaways
4
AAOpt 2026: Understanding the gene therapy landscape for retinitis pigmentosa
5